180 related articles for article (PubMed ID: 23323327)
1. [Comparative in vitro study of anticoagulant activity of RA36 DNA aptamer in human, rabbit, and rat blood plasma].
Savchik EIu; Kalinina TB; Drozd NN; Makarov VA; Zav'ialova EG; Lapsheva EN; Babiĭ AV; Mudrik NN; Pavlova GV; Golovin AV; Kopylov AM
Eksp Klin Farmakol; 2012; 75(11):13-8. PubMed ID: 23323327
[TBL] [Abstract][Full Text] [Related]
2. Aptamer RA36 inhibits of human, rabbit, and rat plasma coagulation activated with thrombin or snake venom coagulases.
Savchik EY; Kalinina TB; Drozd NN; Makarov VA; Zav'yalova EG; Lapsheva EN; Mudrik NN; Babij AV; Pavlova GV; Golovin AV; Kopylov AM
Bull Exp Biol Med; 2013 Nov; 156(1):44-8. PubMed ID: 24319726
[TBL] [Abstract][Full Text] [Related]
3. In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry.
Tanaka KA; Szlam F; Rusconi CP; Levy JH
Thromb Haemost; 2009 May; 101(5):827-33. PubMed ID: 19404534
[TBL] [Abstract][Full Text] [Related]
4. Influence of recombinant hirudin on tissue-factor-induced activation of coagulation in rabbits.
Kouz J; Czech J; Nicolay U; Dickneite G
Haemostasis; 1996; 26(4):179-86. PubMed ID: 8872128
[TBL] [Abstract][Full Text] [Related]
5. HD1, a thrombin- and prothrombin-binding DNA aptamer, inhibits thrombin generation by attenuating prothrombin activation and thrombin feedback reactions.
Kretz CA; Cuddy KK; Stafford AR; Fredenburgh JC; Roberts R; Weitz JI
Thromb Haemost; 2010 Jan; 103(1):83-93. PubMed ID: 20062917
[TBL] [Abstract][Full Text] [Related]
6. Self-assembled, bivalent aptamers on graphene oxide as an efficient anticoagulant.
Lai PX; Mao JY; Unnikrishnan B; Chu HW; Wu CW; Chang HT; Huang CC
Biomater Sci; 2018 Jun; 6(7):1882-1891. PubMed ID: 29808843
[TBL] [Abstract][Full Text] [Related]
7. Laboratory assays for the evaluation of recombinant hirudin.
Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
[TBL] [Abstract][Full Text] [Related]
8. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis.
Pöschel KA; Bucha E; Esslinger HU; Ulbricht K; Nörtersheuser P; Stein G; Nowak G
Kidney Int; 2004 Feb; 65(2):666-74. PubMed ID: 14717940
[TBL] [Abstract][Full Text] [Related]
9. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
Morishima Y; Honda Y; Kamisato C; Shibano T
Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
[TBL] [Abstract][Full Text] [Related]
10. A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity.
Bompiani KM; Monroe DM; Church FC; Sullenger BA
J Thromb Haemost; 2012 May; 10(5):870-80. PubMed ID: 22385910
[TBL] [Abstract][Full Text] [Related]
11. Anticoagulant activity of the novel thrombin inhibitor 1-butyl-3-(6,7-dimethoxy-2-naphthylsulfonyl) amino-3-(3-guanidinopropyl)-2-pyrrolidinone hydrochloride.
Okayama T; Araki S; Miyamae T; Morita Y; Morikawa T; Hagiwara M
Arzneimittelforschung; 1997 Sep; 47(9):1023-6. PubMed ID: 9342415
[TBL] [Abstract][Full Text] [Related]
12. Preparation and anticoagulation activity of sodium cellulose sulfate.
Wang ZM; Li L; Zheng BS; Normakhamatov N; Guo SY
Int J Biol Macromol; 2007 Oct; 41(4):376-82. PubMed ID: 17602735
[TBL] [Abstract][Full Text] [Related]
13. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Warkentin TE; Greinacher A; Craven S; Dewar L; Sheppard JA; Ofosu FA
Thromb Haemost; 2005 Nov; 94(5):958-64. PubMed ID: 16363236
[TBL] [Abstract][Full Text] [Related]
14. Presence of direct thrombin inhibitors can affect the results and interpretation of lupus anticoagulant testing.
Genzen JR; Miller JL
Am J Clin Pathol; 2005 Oct; 124(4):586-93. PubMed ID: 16146819
[TBL] [Abstract][Full Text] [Related]
15. Anticoagulant Activities of Indobufen, an Antiplatelet Drug.
Liu J; Xu D; Xia N; Hou K; Chen S; Wang Y; Li Y
Molecules; 2018 Jun; 23(6):. PubMed ID: 29914049
[TBL] [Abstract][Full Text] [Related]
16. Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma.
Koestenberger M; Gallistl S; Muntean W; Leschnik B; Fritsch P; Cvirn G
Thromb Haemost; 2005 Jul; 94(1):69-74. PubMed ID: 16113786
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers.
Marbet GA; Verstraete M; Kienast J; Graf P; Hoet B; Tsakiris DA; Silling-Engelhardt G; Close P
J Cardiovasc Pharmacol; 1993 Sep; 22(3):364-72. PubMed ID: 7504125
[TBL] [Abstract][Full Text] [Related]
18. [Experimental studies on anticoagulant activity of different extract of leech in vitro].
Li Y; Huang R; Sun X
Zhong Yao Cai; 2004 Feb; 27(2):123-5. PubMed ID: 22455002
[TBL] [Abstract][Full Text] [Related]
19. Anticoagulant property of a semi-synthesized sodium beta-1,4-glucan sulfate.
Wang ZM; Li L; Li B; Guo SY
Yao Xue Xue Bao; 2006 Apr; 41(4):323-7. PubMed ID: 16856476
[TBL] [Abstract][Full Text] [Related]
20. [A study of human annexin V derivative: its effects of anticoagulation and antithrombosis].
Ju CW; Wang LS; Yang X; Ma GS; Hua ZC; Gao XY
Zhonghua Xue Ye Xue Za Zhi; 2004 Sep; 25(9):540-3. PubMed ID: 15569533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
